Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
4/27/26 Mundipharma Rezzayo for Fungal Infections - Systemic Subscribers Only Subscribers Only Subscribers Only
4/27/26 Mundipharma Rezzayo for Candidiasis Subscribers Only Subscribers Only Subscribers Only
4/27/26 Compass Therapeutics (CMPX) tovecimig for Biliary Tract Cancer Subscribers Only Subscribers Only Subscribers Only
4/23/26 Novo Nordisk (NVO) Rybelsus for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
4/23/26 AbbVie (ABBV) Trenibote for Wrinkles Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results